What Are the Surgical Options in Patients with Synchronous Rectal Cancer?

  • Johannes H. W. de Wilt
  • Martinus J. van Amerongen
  • Jorine ‘t Lam-Boer


Approximately 20–25% of patients with rectal cancer present with metastatic disease at the time of diagnosis. The incidence of metastases varies between different stages, where patients with locally advanced or node-positive tumors have a higher risk for metastatic disease compared to patients with early tumors. The risk and pattern of metastasis are also highly dependent on histological subtype. Patients with rectal cancer and distant metastases are nowadays accurately staged, and appropriate treatment regimens can be applied to each patient. Treatment of patients who present with rectal cancer and distant metastases depends primarily on the condition, age, and frailty of the patients, but obviously resectability of the primary tumor and the metastases is important. Involvement of modern multimodality treatment and thorough discussions in a multidisciplinary tumor board is important in optimizing patient outcome.


  1. 1.
    van der Pool AE et al (2012) Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Color Dis 14(1):56–61CrossRefGoogle Scholar
  2. 2.
    van der Geest LG et al (2015) Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis 32(5):457–465CrossRefPubMedGoogle Scholar
  3. 3.
    Hugen N et al (2014) Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol 25(3):651–657CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Schmoll HJ et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23(10):2479–2516CrossRefPubMedGoogle Scholar
  5. 5.
    Kanas GP et al (2012) Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 4:283–301PubMedPubMedCentralGoogle Scholar
  6. 6.
    Morris EJ et al (2010) Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 97(7):1110–1118CrossRefPubMedGoogle Scholar
  7. 7.
    Ayez N et al (2013) Preoperative FDG-PET-scan in patients with resectable colorectal liver metastases does not improve overall survival: a retrospective analyses stratified by clinical risk score. Dig Surg 30(4–6):451–458CrossRefPubMedGoogle Scholar
  8. 8.
    t Lam-Boer J et al (2015) Large variation in the utilization of liver resections in stage IV colorectal cancer patients with metastases confined to the liver. Eur J Surg Oncol 41(9):1217–1225CrossRefGoogle Scholar
  9. 9.
    Nordlinger B et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77(7):1254–1262CrossRefPubMedGoogle Scholar
  10. 10.
    Fong Y et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318. discussion 318-21CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rees M et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247(1):125–135CrossRefPubMedGoogle Scholar
  12. 12.
    Dexiang Z et al (2012) Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases. Ann Surg Oncol 19(9):2860–2868CrossRefPubMedGoogle Scholar
  13. 13.
    Bockhorn M et al (2008) Survival of patients with synchronous and metachronous colorectal liver metastases – is there a difference? J Gastrointest Surg 12(8):1399–1405CrossRefPubMedGoogle Scholar
  14. 14.
    Miller G et al (2007) Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 205(2):231–238CrossRefPubMedGoogle Scholar
  15. 15.
    Nordlinger B et al (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European colorectal metastases treatment group. Eur J Cancer 43(14):2037–2045CrossRefPubMedGoogle Scholar
  16. 16.
    Alberts SR, Poston GJ (2011) Treatment advances in liver-limited metastatic colorectal cancer. Clin Colorectal Cancer 10(4):258–265CrossRefPubMedGoogle Scholar
  17. 17.
    Jones RP et al (2012) Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 99(9):1263–1269CrossRefPubMedGoogle Scholar
  18. 18.
    Folprecht G et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1):38–47CrossRefPubMedGoogle Scholar
  19. 19.
    Andres A et al (2015) Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases. Br J Surg 102(6):691–699CrossRefPubMedGoogle Scholar
  20. 20.
    Kuijpers AM et al (2013) Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 20(13):4224–4230CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Nordlinger B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14(12):1208–1215CrossRefPubMedGoogle Scholar
  22. 22.
    Ayez N et al (2015) The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur J Surg Oncol 41(7):859–867CrossRefPubMedGoogle Scholar
  23. 23.
    Rahbari NN et al (2014) Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer 14:174CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ayez N et al (2015) Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC Cancer 15:180CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mentha G et al (2008) ‘Liver first’ approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg 25(6):430–435CrossRefPubMedGoogle Scholar
  26. 26.
    Verhoef C et al (2009) The “liver-first approach” for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum 52(1):23–30CrossRefPubMedGoogle Scholar
  27. 27.
    Ayez N et al (2013) Long-term results of the “liver first” approach in patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum 56(3):281–287CrossRefPubMedGoogle Scholar
  28. 28.
    Li ZQ et al (2013) Meta-analysis of simultaneous versus staged resection for synchronous colorectal liver metastases. Hepatol Res 43(1):72–83CrossRefPubMedGoogle Scholar
  29. 29.
    Silberhumer GR et al (2014) Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. Am J Surg 206:935–942Google Scholar
  30. 30.
    Capussotti L et al (2007) Major liver resections synchronous with colorectal surgery. Ann Surg Oncol 14(1):195–201CrossRefPubMedGoogle Scholar
  31. 31.
    Kelly ME et al (2015) Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. J Surg Oncol 111(3):341–351CrossRefPubMedGoogle Scholar
  32. 32.
    Siriwardena AK et al (2014) Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol 11(8):446–459CrossRefPubMedGoogle Scholar
  33. 33.
    Adam R et al (2007) Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am 16(3):525–536. viiiCrossRefPubMedGoogle Scholar
  34. 34.
    Fusai G, Davidson BR (2003) Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg 20(6):481–496CrossRefPubMedGoogle Scholar
  35. 35.
    Pathak S et al (2011) Ablative therapies for colorectal liver metastases: a systematic review. Color Dis 13(9):e252–e265CrossRefGoogle Scholar
  36. 36.
    Homayounfar K et al (2014) Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases. Br J Surg 101(5):550–557CrossRefPubMedGoogle Scholar
  37. 37.
    Huiskens J et al (2015) Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch colorectal cancer group (DCCG). BMC Cancer 15:365CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Wong SL et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28(3):493–508CrossRefPubMedGoogle Scholar
  39. 39.
    Crocetti L, de Baere T, Lencioni R (2010) Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 33(1):11–17CrossRefPubMedGoogle Scholar
  40. 40.
    Hompes D, Prevoo W, Ruers T (2011) Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin. Cancer Imaging 11:23–30PubMedPubMedCentralGoogle Scholar
  41. 41.
    Elferink MA et al (2010) Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer 46(8):1421–1429CrossRefPubMedGoogle Scholar
  42. 42.
    Bacon HE, Martin PV (1964) The rationale of palliative resection for primary cancer of the Colon and Rectum complicated by liver and lung metastasis. Dis Colon Rectum 7:211–217CrossRefPubMedGoogle Scholar
  43. 43.
    Takahashi H et al (2015) Self-expanding metallic stents versus surgical intervention as palliative therapy for obstructive colorectal cancer: a meta-analysis. World J Surg 39(8):2037–2044CrossRefPubMedGoogle Scholar
  44. 44.
    Eisenberger A, Whelan RL, Neugut AI (2008) Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Color Dis 23(6):559–568CrossRefGoogle Scholar
  45. 45.
    Chau I et al (2006) Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24(4):668–674CrossRefPubMedGoogle Scholar
  46. 46.
    Poultsides GA, Paty PB (2011) Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective. Ther Adv Med Oncol 3(1):35–42CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Nash GM et al (2002) Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol 9(10):954–960CrossRefPubMedGoogle Scholar
  48. 48.
    Suarez J et al (2015) Complications from the primary tumour are not related with survival in patients with synchronous stage IV colorectal cancer receiving chemotherapy without primary tumour resection. Int J Color Dis 30:1357–1363CrossRefGoogle Scholar
  49. 49.
    Poultsides GA et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27(20):3379–3384CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Yun JA et al (2014) Risk factors for the requirement of surgical or endoscopic interventions during chemotherapy in patients with uncomplicated colorectal cancer and unresectable synchronous metastases. J Surg Oncol 110(7):839–844CrossRefPubMedGoogle Scholar
  51. 51.
    Venderbosch S et al (2011) Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 18(12):3252–3260CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Tarantino I et al (2015) Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients: a population-based, propensity score-adjusted trend analysis. Ann Surg 262(1):112–120CrossRefPubMedGoogle Scholar
  53. 53.
    Sarela AI et al (2001) Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 88(10):1352–1356CrossRefPubMedGoogle Scholar
  54. 54.
    van de Velde CJ (2015) Surgery: palliative primary tumour resection in mCRC-debate continues. Nat Rev Clin Oncol 12(3):129–130CrossRefPubMedGoogle Scholar
  55. 55.
    t Lam-Boer J et al (2014) The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch colorectal cancer group (DCCG). BMC Cancer 14:741CrossRefGoogle Scholar
  56. 56.
    Rahbari NN et al (2012) Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS – a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer 12:142CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Johannes H. W. de Wilt
    • 1
  • Martinus J. van Amerongen
    • 2
  • Jorine ‘t Lam-Boer
    • 1
  1. 1.Department of SurgeryRadboud University Medical CenterNijmegenThe Netherlands
  2. 2.Department of Radiology and Nuclear MedicineRadboud University Medical CenterNijmegenThe Netherlands

Personalised recommendations